Williams Victoria L, Gerlach Anthony T
The Ohio State University Wexner Medical Center, Columbus, Ohio, USA.
Pharmacotherapy. 2025 Mar;45(3):161-168. doi: 10.1002/phar.70000. Epub 2025 Feb 13.
The use of serum creatinine (SCr) for drug dosing has significant limitations and is influenced by many non-kidney factors. Cystatin C (cysC) is an alternative or additional marker of kidney function that is less affected by non-kidney factors. Although cysC may be useful in hospitalized patients, the use of cysC to calculate drug dosing in critically ill patients has been incompletely investigated.
The objective of this study was to determine the rate of discordance in estimated glomerular filtration rate (eGFR) between SCr-based calculations and SCr/cysC-based calculations that affect drug dosing in critically ill patients.
This was a single-center, retrospective, observational cohort study at an academic medical center including critically ill adult patients admitted in 2023 with SCr and cysC ordered. Data were collected via chart review. Demographic data were analyzed via descriptive statistics. Discordance, defined as the percentage of times at which there is at least one discrepancy in kidney dosing for a medication using Cockcroft-Gault (CG) creatinine clearance versus Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) eGFR creatinine-cystatin C (eGFRcr-cys) equations, was analyzed via Wilcoxon matched pair signed ranked sum. eGFR calculations were normalized for patients' body surface area for comparison.
The study population included 232 patients (53.02% female; mean age 58.7 +/- 14.9 years; with 62.5% in medical, 23.28% in surgical, and 8.62% in neurological intensive care) with a median SCr of 0.94 mg/dL IQR [0.57-1.58] and median cysC of 1.92 mg/L IQR [1.27-2.77]. The median clearance rates were 68.5 mL/min (45.3-111.5) for CG and 53.9 mL/min (30.9-80.7) for CKD-EPI eGFRcr-cys; p < 0.001. The discordance rate across all study drugs was 32.3% (75/232). The four most common study drugs demonstrating discordance were cefepime 40.6% (52/128), vancomycin 38.3% (46/120), levetiracetam 35.1% (13/37), and piperacillin/tazobactam 11.6% (5/43).
Clinically significant discordance exists between SCr and SCr/cysC-based estimates of kidney function. This study established a discordance rate, as defined by drug dosing, of 32.3% in adult patients admitted to the ICU.
使用血清肌酐(SCr)进行药物剂量计算存在显著局限性,且受多种非肾脏因素影响。胱抑素C(cysC)是一种肾功能替代或补充标志物,受非肾脏因素影响较小。虽然cysC可能对住院患者有用,但在危重症患者中使用cysC计算药物剂量的研究尚不充分。
本研究的目的是确定基于SCr的计算与基于SCr/cysC的计算之间估计肾小球滤过率(eGFR)的不一致率,这些不一致会影响危重症患者的药物剂量。
这是一项在学术医疗中心进行的单中心、回顾性、观察性队列研究,纳入了2023年入院且检测了SCr和cysC的成年危重症患者。通过病历审查收集数据。人口统计学数据通过描述性统计进行分析。不一致率定义为使用Cockcroft-Gault(CG)肌酐清除率与慢性肾脏病流行病学协作组(CKD-EPI)eGFR肌酐-胱抑素C(eGFRcr-cys)方程计算药物肾脏剂量时至少存在一处差异的次数百分比,通过Wilcoxon配对符号秩和检验进行分析。为便于比较,对患者的体表面积进行了eGFR计算标准化。
研究人群包括232例患者(女性占53.02%;平均年龄58.7±14.9岁;内科患者占62.5%,外科患者占23.28%,神经重症患者占8.62%),SCr中位数为0.94mg/dL,四分位间距[IQR]为[0.57 - 1.58],cysC中位数为1.92mg/L,IQR为[1.27 - 2.77]。CG法的清除率中位数为68.5mL/min(45.3 - 111.5),CKD-EPI eGFRcr-cys法为53.9mL/min(30.9 - 80.7);p < 0.001。所有研究药物的不一致率为32.3%(75/232)。显示不一致的四种最常见研究药物为头孢吡肟40.6%(52/128)、万古霉素38.3%(46/120)、左乙拉西坦35.1%(13/37)和哌拉西林/他唑巴坦11.6%(5/43)。
基于SCr和基于SCr/cysC的肾功能估计之间存在具有临床意义的不一致。本研究确定,在入住ICU的成年患者中,按药物剂量定义的不一致率为32.3%。